Lynn Anne Bristol

Array ( [id] => 17687772 [patent_doc_number] => 20220195064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => ANTI-CD371 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/692979 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17692979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672741 [patent_doc_number] => 20220185908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => METHODS OF USE OF ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/685216 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 295 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672739 [patent_doc_number] => 20220185906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/685201 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 267 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672741 [patent_doc_number] => 20220185908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => METHODS OF USE OF ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/685216 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 295 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18005008 [patent_doc_number] => 20220363774 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2022-11-17 [patent_title] => ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/685206 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 267 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18005008 [patent_doc_number] => 20220363774 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2022-11-17 [patent_title] => ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/685206 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 267 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687773 [patent_doc_number] => 20220195065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16 FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/682367 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -105 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672699 [patent_doc_number] => 20220185866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => TNFRSF14 / HVEM PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/681737 [patent_app_country] => US [patent_app_date] => 2022-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792151 [patent_doc_number] => 20220251242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => MODIFIED ANTIGEN BINDING POLYPEPTIDE CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/652557 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17652557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987785 [patent_doc_number] => 20240059754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => CHIMERIC ANTIGEN RECEPTORS AND ENHANCEMENT OF ANTI-TUMOR ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/590983 [patent_app_country] => US [patent_app_date] => 2022-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17590983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851938 [patent_doc_number] => 20220281980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/582913 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17582913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749636 [patent_doc_number] => 20220227840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => ENGINEERED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/648747 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17648747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720507 [patent_doc_number] => 20220213227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 17/581624 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17581624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738325 [patent_doc_number] => 12215143 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Anti-polyubiquitin multispecific antibodies [patent_app_type] => utility [patent_app_number] => 17/576344 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 34845 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1081 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578822 [patent_doc_number] => 20220135677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => ANTI-SIRP ALPHA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/576109 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17577028 [patent_doc_number] => 20220133883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => METHOD FOR ELICITING AN IMMUNE RESPONSE TO AN IMMUNOGEN [patent_app_type] => utility [patent_app_number] => 17/576800 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929851 [patent_doc_number] => 20220324976 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => NOVEL ANTI-CD4 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/573640 [patent_app_country] => US [patent_app_date] => 2022-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 437 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18207424 [patent_doc_number] => 20230053681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => COMPOSITIONS AND METHODS FOR CROSSLINKING FC RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/573145 [patent_app_country] => US [patent_app_date] => 2022-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578805 [patent_doc_number] => 20220135660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 Region [patent_app_type] => utility [patent_app_number] => 17/571794 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704585 [patent_doc_number] => 20220204591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/569487 [patent_app_country] => US [patent_app_date] => 2022-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17569487 [rel_patent_id] =>[rel_patent_doc_number] =>)